Market Performance - The A-share market showed signs of recovery with the CSI 300 index rising by 1.95% and the ESG 300 index increasing by 2.62% during the week of December 22-26, 2025[5] - The average daily trading volume across the A-share market was approximately 3.22 trillion yuan, indicating a contraction in liquidity[5] ESG Fund Issuance - A total of 3 new ESG funds were launched in December 2025, with a total issuance of 810 million units, primarily focused on social responsibility and corporate governance[10] - Over the past year, 209 ESG public funds were issued, totaling 109.459 billion units[10] - The total net asset value of existing ESG funds reached 1,166.671 billion yuan, with ESG strategy funds accounting for the largest share at 45.01%[10] Fund Performance - The top-performing fund for the week was Guotai Asset's New Energy A, with a weekly return of 13.38% and a year-to-date return of 75.30%[11] - Guotai Asset's New Energy A and GF Carbon Neutral Theme A outperformed their benchmark returns by 10.86% and 8.48%, respectively[12] Green Bond Issuance - In December 2025, a total of 153 ESG bonds were issued, amounting to 120.2 billion yuan[14] - The total issuance of ESG bonds over the past year reached 1,343.43 billion yuan, with 3,882 ESG bonds currently outstanding[14] - The existing ESG bond market has a total size of 5.74 trillion yuan, with green bonds making up the largest share at 62.11%[14] Bank Wealth Management Products - In December 2025, 144 ESG wealth management products were issued, primarily focusing on pure ESG and environmental protection themes[19] - The total number of existing ESG bank wealth management products is 1,215, with pure ESG products representing the largest share at 53.42%[19] Risk Factors - Potential risks include insufficient ESG policy enforcement, lack of standardized data reporting, and lower-than-expected product issuance scales[21]

国泰海通晨报 国泰海通证券股份有限公司 研究所 [Table_Summary] 1、【宏观研究】：宽松预期、供给紧张、地缘风险等多方面因素共同推升金银铜等金属价格连续 创下新高，人民币汇率在企业结汇潮的推动下破 7。关注美联储主席最终提名的揭晓。 2、【策略研究】：站在岁末年初，中国股市有望走出关键一步，跨越和站稳重要关口。远望 2026 年，中国"转型牛"又见新峰。新兴科技是主线，周期消费看转型，继续看好大金融。 2025 年 12 月 29 日 大宗商品普遍上涨。其中，COMEX 铜上涨 6.7%，伦敦金现上涨 4.4%，南华商品指数上涨 4.0%，标 普-高盛商品指数上涨 1.6%，IPE 布油期货上涨 0.4%。 债市方面，10 年期美债收益率及中债总全价指数较前一周维持不变，国内 10Y 国债期货价格上涨 0.14%。 3、【金属新材料研究】有色金属：在供需紧平衡的状况下，供需平衡表很重要，但更需关注宏观 对金属价格走势的核心影响，货币政策、宏观预期、地缘博弈与供给扰动将成为胜负手。工业金 属是流动性+传统复苏+AI 需求的三击。 4、【军工研究】军工：上海证券交易所制定了《上海证券交易所发行上市审 ...

Investment Rating - The report assigns an "Accumulate" rating for the industry [1] Core Insights - The People's Bank of China and eight other departments have issued opinions to enhance financial support for the construction of the Western Land-Sea New Corridor, which will optimize the cross-border trade settlement system and further expand the use of the Renminbi [2][4] - The report emphasizes the importance of the Western Land-Sea New Corridor as a significant international logistics channel, connecting the Silk Road Economic Belt and the 21st Century Maritime Silk Road, which will facilitate the expansion of Renminbi usage [4] - Digital Renminbi is expected to see new development opportunities, leveraging its advantages in payment and settlement, and exploring its application in various scenarios [4] Summary by Sections Financial Support Measures - The report outlines 21 key measures aimed at improving the financial organization collaboration system, constructing a high-quality capital circulation system, and enhancing cross-border financial regulatory cooperation [4] Cross-Border Trade Settlement - The report supports banks in facilitating compliant trade settlements for quality enterprises and encourages the use of Renminbi in cross-border transactions, particularly with Southeast Asia and Central Asia [4] Digital Renminbi Development - The report highlights the potential for digital Renminbi to create innovative solutions through smart contracts and expand its cross-border application [4] Investment Recommendations - The report suggests focusing on related industry chains such as banking IT systems, payment ecosystems, and financial infrastructure, recommending specific companies for investment [4][5]

Group 1: Zhongsheng Pharma - The core business of Zhongsheng Pharma has stabilized after experiencing centralized procurement, with innovative drug research and development gradually yielding results, particularly in respiratory and metabolic fields [2][4] - The company reported a revenue of 1.889 billion yuan for the first three quarters of 2025, a year-on-year decrease of 1.01%, while net profit attributable to shareholders increased by 68.40% to 251 million yuan [4] - The core products of traditional Chinese medicine have maintained stable growth post-collective procurement, with sales resilience supported by volume compensating for price reductions [4][5] - The innovative pipeline includes RAY1225 injection, a dual-target drug for weight loss and blood sugar reduction, which has shown positive results in clinical trials [5] Group 2: Medical Device Industry - The brain-computer interface (BCI) industry in China has achieved rapid development under policy support, with a focus on establishing a robust technological and industrial framework by 2027 [6][8] - The National Medical Products Administration held a meeting to discuss the advancement of BCI medical devices, emphasizing safety and effectiveness as primary considerations [17] - By 2030, the BCI industry aims to cultivate globally influential leading enterprises and a competitive industrial ecosystem, with significant advancements expected in technology and application [18]

Macro Research - The core viewpoint of the report indicates that the US economy showed resilience in Q3 2025, with a GDP growth rate of 4.3%, surpassing expectations of 3.3% and the previous value of 3.8% [3][20] - Key drivers of this resilience include strong personal consumption, increased public spending, and enhanced export contributions, with capital market wealth effects supporting consumer spending [3][20] - The report highlights a "K" shaped economic divergence, characterized by income disparities affecting consumption, varying business conditions between large and small enterprises, and differences in investment growth between new and old economies [4][21] Strategy Research - The report emphasizes that Chinese companies are entering a new phase of globalization, aiming to capture high-value segments of the global value chain [9][25] - It notes that the acceleration of Chinese enterprises going abroad is a strategic response to rising domestic costs and tightening external market access, which is essential for high-quality development [9][25] - The report predicts that the demand for capital goods in China will remain strong, driven by industrialization and infrastructure investment in emerging markets [11][27] Biopharmaceutical Research - The report discusses the release of the sixth batch of medical device procurement documents, indicating a moderate expected price drop and a favorable situation for domestic manufacturers to increase market share [13][29] - It provides specific data on the expected demand for various medical devices, highlighting the market shares of different companies in the procurement process [30][32] - The report maintains a "buy" rating for companies likely to benefit from the procurement, such as Lepu Medical and Mindray Medical [29][30]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [1][18] Core Insights - The company is a pioneer in AGI technology commercialization, with rapid deployment of AI solutions in daily life and healthcare sectors. The AI solutions and medical markets are experiencing fast growth [2][10] - The company is expected to achieve revenues of RMB 12.68 billion, RMB 19.43 billion, and RMB 26.59 billion for the years 2025 to 2027, representing year-on-year growth rates of 35%, 53%, and 37% respectively. The net profit attributable to the parent company is projected to be -RMB 2.45 billion, -RMB 1.35 billion, and -RMB 1.04 billion for the same years, with growth rates of 46%, 45%, and 23% respectively [10][18] Financial Summary - Total revenue is projected to grow from RMB 727.32 million in 2023 to RMB 2,659.25 million by 2027, with annual growth rates of 21.1%, 29.1%, 35.0%, 53.2%, and 36.9% [4][10] - Gross profit is expected to increase from RMB 294.51 million in 2023 to RMB 1,069.12 million in 2027 [4] - The company’s net profit is forecasted to improve from -RMB 375.46 million in 2023 to -RMB 103.67 million in 2027 [4] Market Position - The company ranks fourth in the Chinese AI solutions market, with a market size of RMB 1,804 billion in 2024 and a compound annual growth rate (CAGR) of 33.7% expected until 2030 [10] - In the daily life AI solutions market, the company holds the third position, while in the medical AI market, it ranks fourth [10] Business Segmentation - Revenue from daily life solutions is projected to grow significantly, with expected revenues of RMB 622.53 million in 2024, RMB 819.79 million in 2025, and RMB 1,250.88 million in 2026 [13] - The AI medical segment is anticipated to generate revenues of RMB 199.18 million in 2024, RMB 279.33 million in 2025, and RMB 445.58 million in 2026, with growth rates of 34.36%, 40.24%, and 59.52% respectively [13][14] Valuation - The report employs two valuation methods, resulting in a target price of HKD 451.33 based on a cautious approach [18] - The PS valuation method indicates a reasonable valuation of HKD 451.33, while the PSG method suggests a higher valuation of HKD 527.62 [17][18]

Group 1: Biopharmaceutical Research - The small nucleic acid drug industry is entering a new era with a focus on siRNA drugs for common diseases, driven by mature technology platforms and expanding indications [1][2] - siRNA drugs have transitioned from rare diseases to common diseases, showing strong commercial potential in areas like cardiovascular diseases and chronic hepatitis B [2][3] - The industry is witnessing active business development (BD) transactions, particularly involving Chinese companies leveraging their engineering advantages in small nucleic acid technology [3][4] Group 2: Automotive Research - Bertli's new "small diameter caliper technology" is expected to enhance its market share in the braking sector, aligning with the automotive industry's cost-reduction trends [6][30] - The company has received recognition for its innovative technology, which reduces vehicle weight by 4.4 kg (17% reduction), improving energy efficiency and vehicle handling [30][31] - Bertli is establishing a subsidiary focused on electric motor systems for chassis, aiming to strengthen its position in intelligent driving and robotics [31] Group 3: Food and Beverage Research - The expansion of domestic demand has been elevated to a strategic level, with the consumption sector expected to rebound [8][9] - The liquor sector, particularly Wuliangye, is targeting high-quality sales and market share growth for 2026, while the dairy industry is anticipated to experience a cyclical reversal [9][11] - Structural growth is expected in the beverage sector, with companies like Dongpeng Beverage and Nongfu Spring positioned for significant gains [11] Group 4: Transportation Research - 吉祥航空 is expected to see a gradual reduction in the impact of flight maintenance issues in 2026, with significant profit potential driven by industry recovery and fleet turnover [12][13] - The company has a robust network that is projected to yield substantial profits as the aviation market improves [12][28] - The introduction of the B787 aircraft is expected to enhance international operations, with optimistic long-term profitability forecasts [29]

Group 1: Market Trends and Logic - Domestic demand is becoming the core focus, with policies emphasizing the expansion of domestic demand strategy, indicating a shift in market attention[2] - The glass industry is experiencing accelerated cold repairs, with supply clearing out, but individual stock performance will depend on differentiated deep processing capabilities[3] - The cement industry is expected to benefit from policy execution and governance improvements, with overseas expansion providing growth opportunities[24] Group 2: Investment Recommendations - Focus on companies with independent growth or valuation advantages in the consumption building materials sector, such as Rain虹, Han高, and San棵树[18] - China National Building Material is recommended due to its strong market position and potential for overseas growth, with expected profits of 2-3 billion RMB in 2025[12] - Recommendations for companies with high dividend yields include Tu宝, Wei星, and Bei新, which are expected to benefit from changing market styles[9] Group 3: Industry Performance and Forecasts - The cement sector is projected to see a recovery in profitability, with Huaxin Cement expected to contribute over 10 billion RMB in profits in 2026[12] - The glass market is facing price adjustments, with the average price of float glass at 1151.40 RMB/ton, down 13.65 RMB/ton from the previous week[35] - The construction materials industry is expected to stabilize, with a focus on companies that can deliver performance and customer validation[8]

资产概览：中债牛陡，白银领涨 [Table_Authors] 方奕(分析师) ——资产配置全球跟踪 2025 年 12 月第 3 期 本报告导读： 12/15-12/19，全球资产走势分化显著，发达/欧洲权益涨，新兴/亚洲权益跌。COMEX 银单周涨幅达 9.4%，年内涨幅破 120%。美联储 2026 年降息预期时间提前。 投资要点： 策略研究 /[Table_Date] 2025.12.22 | | 021-38031658 | | --- | --- | | | fangyi2@gtht.com | | 登记编号 | S0880520120005 | | | 郭佼佼(分析师) | | | 021-38031042 | | | guojiaojiao2@gtht.com | | 登记编号 | S0880523070002 | [Table_Report] 相关报告 成交活跃度下降，沪深 300 估值领涨 2025.12.21 消费景气线索增多，电子产业增长延续 2025.12.17 资产概览：全球风偏降温，贵金属领涨 2025.12.15 融资资金流入加速，外资重回流入 2025.12.15 海外联储降息 ...

Macro Research - Commodity performance shows copper and gold are strong, while developed markets outperform emerging markets [1][2] - The US job market remains weak but stable, with inflation growth below expectations, leading the Federal Reserve to potentially pause interest rate cuts [1][3] - The Bank of Japan raised rates by 25 basis points as expected, with future gradual increases anticipated [1][4] - The European Central Bank's rate cut cycle may be nearing its end [1][4] Food and Beverage Research - Dongpeng Beverage is enhancing management efficiency, allowing the company to save significant profits to return to channels and consumers, aligning with the trend of consumers valuing high cost-performance in the beverage industry [1][5] - The company is expected to exceed market expectations in product category expansion, particularly in energy drinks, sports drinks, and coffee [5][6] Nuclear Power Equipment Research - The controllable nuclear fusion sector is seeing significant acceleration in bidding, with major contracts awarded for components like magnets and power supplies [1][8] - Trump Media Technology announced a merger with TAE Technologies, aiming to build large fusion power plants to meet energy demands driven by AI [9][10] - The US Department of Energy is investing $87 million to accelerate AI applications in fusion energy research [9][10]